RSS   Newsletter   Contact   Advertise with us

Biohaven Pharmaceutical appoints Michael Heffernan to board

Christian Fernsby | New Haven, Conn., USA | February 3, 2020
Michael HeffernanBiohaven Pharmaceutical Holding Company announced the appointment of Michael Heffernan to its board of directors.
Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial experience.

Mr. Heffernan is a pharmacist and began his career at Eli Lilly and Company where he served in numerous sales and marketing roles.

He most recently served as Founder and CEO of Collegium and remains Chairman of its Board of Directors.

Mr. Heffernan has been an advisor, investor and board member in a number of biopharmaceutical and healthcare services companies.

His recent board memberships include: TyRx (sold to Medtronic), PreCision Dermatology (sold to Valeant), Ocata Therapeutics (sold to Astellas), and Veloxis (Sold to Asahi Kasei).

He is also currently Chairman of the Board of Carisma Therapeutics and of Indalo Therapeutics and is a member of the board of Akebia Therapeutics (AKBA) and Trevi Therapeutics (TRVI).